Eagle Asset Management Inc. Purchases 10,091 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Eagle Asset Management Inc. lifted its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 352,897 shares of the medical equipment provider’s stock after purchasing an additional 10,091 shares during the quarter. Eagle Asset Management Inc. owned about 0.76% of BioLife Solutions worth $9,221,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. 1620 Investment Advisors Inc. bought a new position in BioLife Solutions in the 2nd quarter worth about $35,000. Isthmus Partners LLC raised its stake in BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares in the last quarter. Quest Partners LLC purchased a new stake in BioLife Solutions in the third quarter valued at approximately $57,000. GAMMA Investing LLC lifted its position in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in BioLife Solutions in the 2nd quarter worth approximately $122,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

BLFS has been the topic of several research reports. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. TD Cowen upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright decreased their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Finally, Northland Securities upped their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, BioLife Solutions presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

Insiders Place Their Bets

In other news, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the sale, the executive vice president now directly owns 317,716 shares in the company, valued at approximately $7,593,412.40. This represents a 3.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the transaction, the executive now owns 114,773 shares in the company, valued at approximately $2,883,097.76. This represents a 2.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,644 shares of company stock valued at $1,527,503 in the last ninety days. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Trading Up 2.4 %

NASDAQ BLFS opened at $26.01 on Friday. The firm has a market cap of $1.21 billion, a PE ratio of -24.54 and a beta of 1.88. BioLife Solutions, Inc. has a 1-year low of $11.91 and a 1-year high of $28.88. The stock has a 50-day moving average of $24.00 and a 200-day moving average of $22.95. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.